This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Shi, Y. et al. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nat. Rev. Nephrol. 14, 493–507 (2018).
Xu, J. Immunue modulation by mesenchymal stem cells. Cell Prolif. 53, e12712 (2020).
Wuchter, P. et al. Standardization of Good Manufacturing Practice-compliant production of bone marrow-derived human mesenchymal stromal cells for immunotherapeutic applications. Cytotherapy 17, 128–139 (2015).
Xu, J. et al. Additive therapeutic effects of mesenchymal stem cells and IL-37 for systemic lupus erythematosus. J. Am. Soc. Nephrol. 31, 54–65 (2020).
Reis, M. et al. Global phenotypic characterisation of human platelet lysate expanded MSCs by high-throughput flow cytometry. Sci. Rep. 8, 3907 (2018).
Kong, C. M., Lin, H. D., Biswas, A., Bongso, A. & Fong, C. Y. Manufacturing of human Wharton’s jelly stem cells for clinical use: selection of serum is important. Cytotherapy 21, 483–495 (2019).
Wang, Y. et al. Understanding the immunological mechanisms of mesenchymal stem cells in allogeneic transplantation: from the aspect of major histocompatibility complex class I. Stem Cells Dev. 28, 1141–1150 (2019).
Ankrum, J. A., Ong, J. F. & Karp, J. M. Mesenchymal stem cells: immune evasive, not immune privileged. Nat. Biotechnol. 32, 252–260 (2014).
Deuse, T. et al. Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients. Nat. Biotechnol. 37, 252–258 (2019).
Acknowledgements
This work was supported by the Natural Science Foundation of Shenzhen (JCYJ20180305163407913 and KQJSCX20180328093434771), Guangdong Provincial Science and Technology Program (No. 2019B030301009) and the Medical Foundation of Guangdong (A2018308).
Author information
Authors and Affiliations
Contributions
J.X. designed and supervised the project, interpreted the data, and wrote the manuscript; W.L. conducted the cell culture experiments; H.W. and X.W. conducted the animal studies; J.C., L.Y. and X.Z. collected the clinical samples and conducted the animal studies; and L.L. and Z.H. analyzed the data and corrected the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethics
This study was approved by the ethics committee of Shenzhen University and followed the tenets of the Declaration of Helsinki.
Informed consent
Informed consent was obtained from participants prior to study participation.
Supplementary information
Rights and permissions
About this article
Cite this article
Xu, J., Lian, W., Wu, H. et al. Improved therapeutic consistency and efficacy of mesenchymal stem cells expanded with chemically defined medium for systemic lupus erythematosus. Cell Mol Immunol 17, 1104–1106 (2020). https://doi.org/10.1038/s41423-020-0364-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41423-020-0364-4